Kay Brickmann is a senior director of transactions, business development, and licensing at AstraZeneca and serves as a director of the board at OnDosis. With a PhD in Organic Chemistry from The University of Göttingen, Kay has over 20 years of post-doctoral experience in the pharmaceutical industry, specializing in negotiations and successful transactions across Europe, the USA, Japan, and China. Previously, Kay worked as a postdoctoral fellow in bioorganic chemistry at Lund University and the University of Umea, and held various strategic roles at AstraZeneca. Kay is fluent in German, English, and Swedish.
This person is not in any teams
This person is not in any offices